Explaration of the association between genetic abnormalities and clinicopathological findings in follicular lymphoma

Explaration of the association between genetic abnormalities and clinicopathological findings in follicular lymphoma - Explaration of the association between genetic abnormalities and clinicopathological findings in follicular lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060906

Enrollment

300

Registered

2026-03-13

Start date

2023-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with follicular lymphoma between January 1, 2000, and August 31, 2022, at Nagoya University Hospital or at collaborating institutions that contributed only existing samples and clinical information.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Targeted sequencing will be performed using the Twist Exome 2.0 system for target region enrichment, followed by next-generation sequencing on the DNBSEQ-G400 platform. Sequence reads will be aligned to the reference genome using the "Furo" supercomputer at Nagoya University. Subsequently, variant calling will be conducted on the same system, focusing on approximately 500 genes selected primarily from those specified in the Japanese Society of Hematology's Guidelines for Genomic Testing in Hematologic Malignancies. Fluorescence in situ hybridization (FISH) will be performed for BCL2, BCL6, MYC, and TNFRSF14. Immunohistochemistry will be conducted for CD10, CD20, BCL2, BCL6, MUM1, MIB1, CD21, CD23, CD35, alpha-SMA, kappa, lambda, CD3, PD1, and ICOS. Morphological evaluation by light microscopy will include grading, the proportion of follicular versus diffuse architecture, presence or absence of concomitant DLBCL, marginal zone differentiation, plasmacytic differentiation, and deposition of hyalinized material in the background. Other specific findings might be additionally analyzed in the process of the evaluation. Correlation analyses will then be performed to evaluate the relationships between these pathological findings and underlying genetic abnormalities.	—

Measure

Time frame

Targeted sequencing will be performed using the Twist Exome 2.0 system for target region enrichment, followed by next-generation sequencing on the DNBSEQ-G400 platform. Sequence reads will be aligned to the reference genome using the "Furo" supercomputer at Nagoya University. Subsequently, variant calling will be conducted on the same system, focusing on approximately 500 genes selected primarily from those specified in the Japanese Society of Hematology's Guidelines for Genomic Testing in Hematologic Malignancies. Fluorescence in situ hybridization (FISH) will be performed for BCL2, BCL6, MYC, and TNFRSF14. Immunohistochemistry will be conducted for CD10, CD20, BCL2, BCL6, MUM1, MIB1, CD21, CD23, CD35, alpha-SMA, kappa, lambda, CD3, PD1, and ICOS. Morphological evaluation by light microscopy will include grading, the proportion of follicular versus diffuse architecture, presence or absence of concomitant DLBCL, marginal zone differentiation, plasmacytic differentiation, and deposition of hyalinized material in the background. Other specific findings might be additionally analyzed in the process of the evaluation. Correlation analyses will then be performed to evaluate the relationships between these pathological findings and underlying genetic abnormalities.

—

Countries

Japan

Contacts

Public ContactKennosuke Karube

Graduate School of Medicine, Nagoya University Department of Pathology and Laboratory Medicine

karube@med.nagoya-u.ac.jp052-744-2896

Outcome results